Evofem Biosciences (EVFM) shares new July 2026 investor deck

Q: What did Evofem Biosciences (EVFM) disclose on July 20, 2026?

Evofem Biosciences (EVFM) disclosed that it has prepared a corporate slide presentation as of July 20, 2026 . The deck provides business updates for investors and is furnished as Exhibit 99.1 and posted on the company’s Investors website section.

Q: Where can investors access Evofem Biosciences’ July 20, 2026 corporate presentation?

Investors can access Evofem Biosciences’ July 20, 2026 corporate slide presentation through the Investors section of its website at www.evofem.com. The same presentation is also furnished as Exhibit 99.1 to a report dated July 20, 2026.

Q: Is Evofem Biosciences’ Exhibit 99.1 considered filed or furnished under the Exchange Act?

Evofem Biosciences states that Exhibit 99.1 is furnished, not filed , under the Securities Exchange Act of 1934. As furnished information, it is not subject to Section 18 liabilities and has different legal status than materials formally filed with the SEC.

Q: Does the July 20, 2026 Evofem (EVFM) presentation become part of other SEC filings?

The company states that the July 20, 2026 presentation in Exhibit 99.1 is not incorporated by reference into Securities Act or Exchange Act filings, unless a future filing expressly incorporates it by specific reference.

Q: What other exhibit accompanies Evofem Biosciences’ July 20, 2026 presentation?

Alongside the corporate presentation in Exhibit 99.1, Evofem Biosciences includes Exhibit 104 . Exhibit 104 is described as the Cover Page Interactive Data File, embedded within an Inline XBRL document for reporting and data-tagging purposes.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Evofem Biosciences, Inc. reports that it periodically presents and distributes slide presentations to the investment community to provide updates and summaries of its business. A copy of its current corporate slide presentation, prepared as of July 20, 2026, is being made available on the Investors section of its website.

The same corporate slide deck is furnished as Exhibit 99.1 to a report dated July 20, 2026, together with a Cover Page Interactive Data File as Exhibit 104. The company states that the information in Item 7.01, including Exhibit 99.1, is being furnished and not deemed filed under the Securities Exchange Act of 1934, and is not incorporated by reference into Securities Act or Exchange Act filings unless specifically referenced. The report is signed on behalf of the company by Chief Executive Officer Saundra Pelletier.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Corporate presentation date: July 20, 2026 Exhibit number for presentation: 99.1 Interactive data exhibit: 104

3 metrics

Corporate presentation date July 20, 2026 Prepared as of date for Evofem Biosciences’ corporate slide presentation in Exhibit 99.1

Exhibit number for presentation 99.1 Corporate presentation furnished to investors as Exhibit 99.1

Interactive data exhibit 104 Cover Page Interactive Data File identified as Exhibit 104

Key Terms

corporate slide presentation, Emerging Growth Company, incorporated by reference, Inline XBRL

4 terms

corporate slide presentation financial

"presents and/or distributes to the investment community ... corporate slide presentation"

Emerging Growth Company regulatory

"Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging Growth Company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

incorporated by reference regulatory

"nor shall such information be deemed incorporated by reference in any filing"

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 07/20/2026 - 04:15 PM Accepted by SEC EDGAR 07/20/2026 - 04:14 PM

FAQ

What did Evofem Biosciences (EVFM) disclose on July 20, 2026?

Evofem Biosciences (EVFM) disclosed that it has prepared a corporate slide presentation as of July 20, 2026. The deck provides business updates for investors and is furnished as Exhibit 99.1 and posted on the company’s Investors website section.

Where can investors access Evofem Biosciences’ July 20, 2026 corporate presentation?

Investors can access Evofem Biosciences’ July 20, 2026 corporate slide presentation through the Investors section of its website at www.evofem.com. The same presentation is also furnished as Exhibit 99.1 to a report dated July 20, 2026.

Is Evofem Biosciences’ Exhibit 99.1 considered filed or furnished under the Exchange Act?

Evofem Biosciences states that Exhibit 99.1 is furnished, not filed, under the Securities Exchange Act of 1934. As furnished information, it is not subject to Section 18 liabilities and has different legal status than materials formally filed with the SEC.

Does the July 20, 2026 Evofem (EVFM) presentation become part of other SEC filings?

The company states that the July 20, 2026 presentation in Exhibit 99.1 is not incorporated by reference into Securities Act or Exchange Act filings, unless a future filing expressly incorporates it by specific reference.

Who signed the July 20, 2026 report for Evofem Biosciences (EVFM)?

The report dated July 20, 2026 for Evofem Biosciences (EVFM) was signed on the company’s behalf by Saundra Pelletier. She is identified in the signature block as the company’s Chief Executive Officer.

What other exhibit accompanies Evofem Biosciences’ July 20, 2026 presentation?

Alongside the corporate presentation in Exhibit 99.1, Evofem Biosciences includes Exhibit 104. Exhibit 104 is described as the Cover Page Interactive Data File, embedded within an Inline XBRL document for reporting and data-tagging purposes.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 20, 2026

EVOFEM BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-36754	20-8527075
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

7770 Regents Road, Suite 113-618

San Diego, California 92122

(Address of principal executive offices)

(858) 550-1900

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.

Regulation FD Disclosure.

Evofem Biosciences, Inc. (the “Company”) from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. The Company is posting to the “Investors” portion of its website at www.evofem.com a copy of its current corporate slide presentation. These slides are attached to this Current Report on Form 8-K as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Corporate presentation prepared as of July 20, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.